Collaboration Between Protalix Biotherapeutics and Secarna Pharmaceuticals for Rare Disease Innovations Protalix BioTherapeutics and Secarna Pharmaceuticals have teamed up to develop antisense oligonucleotide therapies targeting rare renal diseases, merging expertise to fill significant medical needs.

Collaboration Between Protalix Biotherapeutics and Secarna Pharmaceuticals for Rare Disease Innovations #United_States #Protalix #Secarna #OligoCreator #Carrying_out_clinical_stages_in_various_locations